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center, cross-sectional cost-of-illness study. Information
as demographic characteristics, consultations, hospital-
izations, rehabilitations, out-of-pocket-expenditures as
for OTC-medication, copayment, skin care products 
and absence from work was collected with a semi-
standardized patient-questionnaire. Resource utilization
of outpatient care was gained from patients’ records.
Direct and indirect costs were considered. RESULTS: 16
centers—10 ofﬁce-based dermatologists, 4 ofﬁce-based
pediatricians, 1 outpatient unit of a dermatology hospi-
tal and 1 patient organization participated. Until now,
189 patients were enrolled at the medical centers. 153
patient questionnaires were sent back (including 53 from
patients of the patient organisation). Mean age of patients
is 24 years (1–71 years) and about 46% are male. About
27% of the patients have a mild course of disease, about
36% a moderate and about 37% a severe or very severe
course of disease. Six out of 153 patients were hospital-
ized due to the current ﬂare (4%). On average, patients’
expenses for OTC-medication and skin care products are
€164 per year, for additional treatment e.g. psycho-
therapy or naturopathy €62 per year and for e.g. special
clothes or nutrition €349 per year. CONCLUSIONS:
Because the study is still ongoing, annual cost data from
the third party payers’ perspective is under evaluation,
and will be ﬁnalized not later than August 2002. But these
preliminary results show that patients and their families
bear are remarkable amount of the annual costs (about
€575) by themselves.
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COST EFFECTIVENESS OF PIMECROLIMUS
(ELIDEL) IN THE TREATMENT OF CHILDREN
WITH ATOPIC DERMATITIS
Grueger J, van Assche D
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OBJECTIVE: To compare the cost-effectiveness of an
Elidel (pimecrolimus cream 1%) in the long-term man-
agement of children with atopic dermatitis. METHODS:
Data were taken from a double-blind, multicenter, ran-
domized, parallel-group study. Patients were randomised
(2 :1) to receive pimecrolimus treatment paradigm 
(i.e. emollients, pimecrolimus, medium potency topical
corticosteroids) or standard of care (emollients, vehicle,
medium potency topical corticosteroids). The study was
conducted in children and adolescents (2 to 18 years of
age, 474 patients on pimecrolimus and 237 patients on
standard of care). Costs were estimated by linking sever-
ity of disease as deﬁned by Investigator’s Global Assess-
ment (IGA) to average treatment costs. Drug costs were
estimated from the clinical trial data. Efﬁcacy was mea-
sured in number of patients with 0 ﬂares over 12 months
(“successfully treated patient”, STP) and average number
of ﬂares as reported in the clinical trial. RESULTS: In 
the children and adolescent study, 68.4% of patients on
pimecrolimus and 43.5% of patients on standard of care
had no ﬂare over the total study period of 12 months, a
difference of 24.9%. The average number of ﬂares in 
the pimecrolimus treatment group was 0.48, compared to
3.36 in the standard of care group, a reduction of 2.88
ﬂares. Patients on pimecrolimus cost GBP 1009, patients
on standard of care GBP 448, an incremental cost of GBP
561 over 12 months. 4.0 patients needed to be treated to
achieve one STP, the cost per STP was GBP 2255 and the
cost per ﬂare avoided was GBP 195. The results were sen-
sitive to the assumption of drug substance used, which is
closely linked to the cost of treatment. CONCLUSIONS:
Pimecrolimus has a very reasonable cost-effectiveness as
measured by the incremental cost per additional success-
fully treated patient and the incremental cost per ﬂare
avoided.
EAR, EYE & SKIN DISEASES/DISORDERS—Clinical
Outcomes
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OBJECTIVE: To estimate and compare the long-term
consequences of IOP control of travoprost, latanoprost
and timolol. METHOD: Daily IOP average, variance,
minimum, and maximum were derived from a 12-month
randomised, double-masked double-dummy, phase III
multi-centre clinical trial comparing travoprost 0.004%
od, latanoprost 0.005% od and timolol 0.5% bid.
Patients had POAG or OH, and IOP was measured at
weeks 2, 12, 24 and 48 at 8:00 am, 10:00 am and 4:00
pm. The Stewart discriminant functions were applied fol-
lowed by a step-by-step threshold responder analysis. The
statistical unit was eye and a second interaction order
analysis of variance was performed including eye, 
time, treatment, and investigator as variables. Sensitivity
analysis was performed on the 5th to 95th-percentile 
range of the discriminant empirical distribution function.
RESULTS: Five hundred and ninety-six patients were ran-
domly assigned to travoprost, timolol, or latanoprost.
Travoprost patients’ daily IOP average was signiﬁcantly
lower than timolol (-1.3mmHg, P < 0.0001) and
latanoprost (-0.3mmHg, P < 0.001). Similar results were
found on daily IOP minimal value (respectively -1.3mm
Hg, P < 0.0001; -0.3mmHg, P < 0.004) and daily IOP
maximal value (respectively -1.5mmHg, P < 0.0001; 
-0.3mmHg, P < 0.02). No difference was found on IOP
variance between the prostaglandins (P < 0.25) while
timolol patients had a higher estimate (-0.60; P < 0.004).
If eight timolol patients were treated instead with
latanoprost, one new VFD would be avoided over ﬁve
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years. If 25 latanoprost patients were treated instead 
with travoprost, one new VFD would be avoided over 
5 years. CONCLUSION: According to our model, the
better control of both mean IOP and IOP variance by
travoprost should better preserve patient vision. Prospec-
tive data collection should be performed to conﬁrm our
ﬁndings.
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OBJECTIVE: To estimate the medical outcome of 
glaucoma/ocular hypertension (OH) treatment in France
according to usual practice. METHODS: Ophthalmolo-
gists selected at random had to include 4 consecutive
patients older than 18 seen in consultation during a week,
2 with glaucoma and 2 with OH. Socio-demographics,
general and eye comorbidities, glaucoma risk factors,
visual acuity (VA), papilla, and visual ﬁelds were col-
lected. A visual ﬁeld defect (VFD) was deﬁned as a dete-
rioration of papilla exam and visual ﬁeld since diagnosis.
A treatment switch was deﬁned as adding a new drug 
or changing any of the current treatments. Time to failure
of a treatment regimen, broken out by the number of
treatment switches, was compared using the likelihood
ratio applied to survival curves. RESULTS: One hundred
and twenty seven of the 337 patients included by the 84
ophthalmologists had their full treatment documented
from diagnosis. Twelve patients developed a new VFD
after diagnosis (average follow-up: 2.5 years). No statis-
tically signiﬁcant difference on the known confounding
factors of VFD was found between patients with and
without VFD. Patients with VFD had a lower VA (-1.23;
P < 0.08). At 3 years, 2.7% of the patients with no treat-
ment switch had a VFD, compared to 22.6% with one
treatment switch and 46.3% with >2 treatment switches.
The difference between the three groups was statistically
signiﬁcant (P < 0.01). CONCLUSION: Patients with
fewer treatment switches have less VFD. Under isotropic
hypotheses, effective treatment strategies should be used
ﬁrst line in order to avoid visual ﬁeld defect and there-
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Skin diseases have a strong impact on physical and mental
well-being of the patient. These diseases can appear at any
age and, generally speaking, they have a greater reper-
cussions on the quality of life of women. Dermatological
conditions often alter the patient’s own body image,
which can cause psychological problems such as depres-
sion, anxiety and even suicide. OBJECTIVE: To evaluate
the depressive symptomatology (DS) of patients with 
psoriasis. The CES-D (Center for Epidemiologic Studies—
Depression scale), a short self-report scale composed of
20 items, is a questionnaire designed to measure DS in
the general population. The CES-D is widely used in epi-
demiological surveys on large populations. METHOD:
One thousand ﬁve hundred CES-D questionnaires were
sent via a psoriasis patients support group: the APLCP.
The questionnaires once completed were sent back trough
a prepaid envelope. RESULTS: Six hundred thirty-seven
questionnaires were returned: response rate: 42.5%. The
sex ratio Men/Women was 46/54. Mean age: 48.9 years.
Mean age of diagnosis: 25.7 years. The average to the
total score was 20.9 (sd:12.5). The preliminary results
showed DS in 48% of patients with psoriasis (versus 19%
in the general population). There is DS in 47.1% of men
and 49.0% of women. Two groups were identiﬁed: 
ﬂare-up of psoriasis (46.7%), psoriasis not in ﬂare-up
(51.8%)—no answers (1.5%). Current episode of 
psoriasis are linked with higher frequency of DS (54.3%
versus 42.4%). Psoriasis had a greater impact on patients
with episode: CES-D score: 22.8 (sd:12.74) than patients
without present episode CES-D score : 19.22 (s.d :11.96).
This difference was signiﬁcant (p < 0.0003). CONCLU-
SION: Psoriasis patients have an increased risk of DS
compared to the general population (48% versus 19%).
A recent episode of psoriasis results in a more important
frequency of DS in patients (54.3% versus 42.4%).
Appropriate disease management and any treatment that
could reduce ﬂare-up frequency would improve patients’
quality of life and help them face their psoriasis.
EAR, EYE & SKIN DISEASES/DISORDERS—Quality
of Life/Utility
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OBJECTIVES: To evaluate the consequences of local
anti-glaucoma drug side effects on the vision-related
quality of life of French patients. METHODS: A mail
survey was sent to 20,000 homes belonging to the Sofres
panel (representative of the French population according
to the quota method) asking whether one member of 
the family was treated with one of the available topical
anti-glaucoma drugs. A computer-assisted telephone
interviewing system was used to conﬁrm self-reported
glaucoma treatment, to describe the disease and its treat-
